Chikungunya virus causes a painful, debilitating arthritis for which there is currently no treatment. A new study has found that combining a drug for rheumatoid arthritis with one that targets the chikungunya virus can eliminate the signs of arthritis in mice in the early stage of the disease.
A large-scale international study involving more than 300 researchers, published today in Nature, heralds the discovery of 83 genetic variations controlling human height. To discover the 83 genetic variations, the research team measured the presence of 250,000 genetic variations in the study’s 700,000 participants – an enormous job. This study paves the way for precision medicine.
In a new paper published this week in PNAS, researchers at the University of California San Diego School of Medicine and Moores Cancer Center, in collaboration with colleagues at Rady Children’s Hospital-San Diego, the University of Colorado School of Medicine and SignalRx, a San Diego-based biopharmaceutical company, describe a potential new class of anti-cancer drugs that inhibit two or more molecular targets at once, maximizing therapeutic efficiency and safety.
Using a process called LASER ART (long-acting slow effective release antiretroviral therapy), a research team has discovered an unexpected pathway to open cell storage areas for antiviral drugs. The discovery could revolutionize current treatments for HIV/AIDS by extending the actions of disease-combating medicines.
A light-sensing protein from a salt-loving, sulfur-forming microbe has proved key to developing methods essential to advanced drug discovery, understanding human vision and other biomedical applications. In a review published this week in Structural Dynamics, by AIP Publishing, physicist Marius Schmidt of the University of Wisconsin‐Milwaukee presents a history of decades of research of this microbe and the many new technologies that have enabled these applications.
Tudor Oprea, MD, PhD, at UNM Comprehensive Cancer Center and his collaborators from the UK-based European Bioinformatics Institute in Hinxton and from the Institute for Cancer Research in London have created the beginnings of an open archive that links a drug’s chemical structure, its molecular biology activity and the diseases it is used to treat.
Baylor Heart and Vascular Services at Fort Worth on Tuesday, November 15, became the first program in Texas to implant the only FDA-approved device designed to prevent blood clots from entering the brain by sealing a hole in the heart. The device is designed to help reduce the risk of recurrent cryptogenic strokes in patients diagnosed with a patent foramen ovale (PFO) – a small opening between the upper chambers of the heart.
The later-in-life effects of early life exposure to inorganic arsenic, reducing the toxicity of cancer treatments, advances in organs-on-a-chip and other alternative test methods, how to translate in vitro research to real-world understanding, controversies in pesticide toxicology, and the reproductive and developmental effects of botanical dietary supplements are just a few of the cutting-edge scientific topics being explored at the Society of Toxicology (SOT) 56th Annual Meeting and ToxExpo.
Researchers who developed and tested a revolutionary laboratory technique that allows for the endless growth of normal and diseased cells in a laboratory are publicly sharing how the technique works.
Pulmospheres, three dimensional multicellular spheroids composed of lung cells from individual patients, were shown to be effective in predicting the efficacy of medications for idiopathic pulmonary fibrosis, according to findings from UAB presented today in JCI Insight.
Researchers from the Chinese Academy of Sciences have discovered that the metabolic enzyme phosphoglycerate mutase 1 (PGAM1) helps cancer cells repair their DNA and found that inhibiting PGAM1 sensitizes tumors to the cancer drug Olaparib (Lynparza). Their findings in the study “Phosphoglycerate mutase 1 regulates dNTP pool and promotes homologous recombination repair in cancer cells,” which has been published in The Journal of Cell Biology, suggest that this FDA-approved ovarian cancer medicine has the potential to treat a wider range of cancer types than currently indicated.
When is it appropriate to treat short children with growth hormone? The answer is not always clear-cut, as many parents and physicians weigh social, medical and ethical concerns. Experts in pediatric endocrinology have issued a new set of guidelines for managing children and teens who have growth failure.
The Robert R. Meyer Foundation is supporting Southern Research’s Drug Discovery program with a $500,000 gift that aims to accelerate efforts to find new treatments for unmet medical conditions and rare and neglected diseases.
Click here to go directly to the Physics News Source Sponsored by AIP.
A team of researchers from Wayne State University has developed a behavioral tool that may significantly aid in understanding the underlying mechanisms of tinnitus, ultimately leading to new drugs and treatment methods.
A team led by scientists at The Scripps Research Institute (TSRI) has developed a versatile new method that should enhance the discovery of new drugs and the study of proteins.
A team of researchers from Case Western Reserve University School of Medicine has helped uncover the elusive structure of a cancer cell receptor protein that can be leveraged to fight disease progression.
Acute myeloid leukaemia study finds personalised therapy is possible.
– Imagine a day when you visit the doctor’s office for your annual physical. Your physician orders routine tests – cholesterol, glucose and blood count – but they also order a sequence of your genome, all 3 billion letters of it. Routine genomic testing is not far away, according to researchers at The University of Texas Health Science Center at Houston (UTHealth).
Amid Trump comments and stock dive, let WUSTL expert on the history of the pharmaceutical industry Michael Kinch walk you through pharma "Valley of Death."
Warfarin is a commonly prescribed blood thinner used to prevent harmful blood clots. However, the drug requires frequent monitoring, daily dosing and can result in serious negative effects when mixed with vitamin K, a vitamin commonly found in vegetables such as lettuce or broccoli. Now, a new study from University of Missouri Health Care has found that using electronic health records (EHR) can improve the care patients receive after they leave the hospital and eliminate potential confusion among care providers and pharmacists.
The Princess Margaret Cancer Foundation is thrilled to announce the successful achievement of our Billion Dollar Challenge, in partnership with the Princess Margaret Cancer Centre at University Health Network.
A Retro94-based compound may prevent a common and sometimes fatal virus, human cytomegalovirus (CMV) from reproducing and protect immunocompromised patients, like those with HIV, on chemotherapy, with transplants and infants from the effects of the disease, according to Penn State College of Medicine researchers.
The Leona M. and Harry B. Helmsley Charitable Trust awarded a $2.5 million grant to the Case Western Reserve University School of Medicine to continue research on a new form of insulin for those living with type 1 diabetes (T1D).
Canadian prostate cancer researchers have discovered the genetic fingerprint that explains why up to 30 per cent of men with potentially curable localized prostate cancer develop aggressive disease that spreads following radiotherapy or surgery.
Canadian and Australian prostate cancer researchers have discovered a key piece in the genetic puzzle of why men born with a BRCA2 mutation may develop aggressive localized cancers that resist treatment and become lethal for up to 50 per cent of patients within five years.
More than 12 months after Parkinson's patient Bill Crawford received "DBS Plus," he can walk more easily and is back to leading services at his beloved Porter Memorial Church in Lexington, Ky.
Vanderbilt University scientists have received notification from the U.S. Food and Drug Administration (FDA) that testing in humans may proceed for an investigational new drug after more than 10 years of research by scientists at Vanderbilt University and Vanderbilt University Medical Center.
Researchers have found that people with advanced head and neck squamous cell carcinoma and the KRAS-variant inherited genetic mutation have significantly improved survival when given a short course of the drug cetuximab in combination with standard chemotherapy and radiation.
A hospital engaged in a quality improvement program launched by ASHP (American Society of Health-System Pharmacists) has identified weaknesses in existing antibiotic stewardship initiatives and implemented workflow changes that resulted in faster antibiotic administration. St. Francis Hospital in Federal Way, Wash., was recently featured in ASHP’s InterSections, which highlights the hospital’s team approach to improving infection treatment with IV antibiotics.
A new way to fight multidrug-resistant bacteria by blinding them rather than killing them proved highly effective in a model of burn injuries, UT Southwestern Medical Center research shows.
Scientists from the Florida campus of The Scripps Research Institute (TSRI) have developed an efficient process to rapidly discover new “enediyne natural products” from soil microbes that could be further developed into extremely potent anticancer drugs.
/PRNewswire/ -- Clarity, a global international scientific research company, based in Austin, Texas, announces the latest results of its IRB-approved OPERA study. OPERA (Optimizing Patient Experience and Response to Topical Analgesics) evaluates patient perceptions of pain treatment with the use of FDA-approved topical/transdermal formulations alone or in combination with neuropathic supplements via a patient-reported survey.
A team of doctors and psychologists examined the effects of structured talk therapy and medication on patients with social anxiety disorders. In doing so they set a new world record in effectively treating social anxiety disorder.
UCLA researchers show the potential of their digital health platform to help treat acute lymphoblastic leukemia by being able to personalize drug dosages and combinations
Most cancer treatments come in the form of chemotherapy given intravenously. This is unique because it uses a combination of two oral medications.
Biochemist Gautam Dantas inspects what’s deposited on infant diapers for clues about antibiotic resistance.
The fine art of mixing drug cocktails is incredibly complicated, with virtually infinite numbers of possible interactions and side effects. Now, a new model from the Weizmann Institute lab of Prof. Uri Alon lets scientists compare combinations of drugs to determine efficacy – a major step forward in personalized medicine.
A new investigational drug originally developed for type 2 diabetes is being readied for human clinical trials in search of the world’s first treatment to impede the progression of Parkinson’s disease following publication of research findings today in the journal Science Translational Medicine.
A Yale Cancer Center team has evaluated the use of hypomethylating agents in patients suffering from Acute Myeloid Leukemia (AML) who were resistant to treatment with intensive chemotherapy.
The Monell Center announced today that it has received a $345,000 grant from the Bill & Melinda Gates Foundation. The grant supports an innovative global health research project titled, "Developing Novel Pediatric Formulation Technologies for Global Health: Human Taste Assays."
The study, “A Real-World Multicentre Retrospective Observational Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line Treatment for HER2-Negative Metastatic Breast Cancer,” was recently published in the Journal of Cell Physiology.
A new study by scientists from the Florida campus of The Scripps Research Institute (TSRI) offers a novel structure-based drug design strategy aimed at altering the basic landscape of this type of breast cancer treatment.
The University of Kentucky Markey Cancer Center recently launched its own Molecular Tumor Board, an approach to cancer care that uses genetic analysis to help oncologists choose cancer therapies tailored to each patient's individual needs. The Molecular Tumor Board is the latest precision medicine initiative to come online at Markey.
The federally funded grant will support bench research aimed at understanding how the protein hormone, parathyroid hormone-a related protein-and a drug analog that mimics the protein called abaloparatide, interact in the surface of a cell in bone and affect bone formation and breakdown.
UTHealth and Purdue Pharma L.P. have entered into a specialized alliance to bring academic researchers and drug developers closer together with the common goals of accelerating the development of new drug therapies for patients while advancing the science and providing unique educational experiences for both.
A team at the Oakland and San Francisco campuses of UCSF Benioff Children’s Hospitals, UCSF, and UC Berkeley have been awarded $1.2 million by California Initiative to Advance Precision Medicine (CIAPM) to help advance precision medicine in the state.
More than 3.8 billion controlled medications, such as hydrocodone, oxycodone, Valium and Adderall, are dispensed by pharmacies annually in the United States. It has been estimated that only about 30 percent of these drugs are used by the people for whom they were prescribed. The remaining 70 percent represent a large surplus of controlled medications that could be abused or sold to others for abuse.
The American Association of Pharmaceutical Scientists is pleased to announce the 2016 Dale E. Wurster recipient, Stephen R. Byrn, Ph.D., of Purdue University. Byrn is recognized for his work in the field of Solid State Chemistry of Drugs. Supported by the Dale E. Wurster Endowment, this award is given to individuals who have made significant contributions to the pharmaceutical sciences in the specific field of pharmaceutics.
A Mayo Clinic study is shedding light on why some rheumatoid arthritis patients respond poorly when treated with tumor necrosis factor inhibitors, part of a class of drugs called biologics.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right